Recurrent blooms of Heterosigma akashiwo (Raphidophyceae) in the Piraquê Channel, Rodrigo de Freitas Lagoon, southeast Brazil / Florações recorrentes de Heterosigma akashiwo (Raphydophyceae) no Canal do Piraquê, Lagoa Rodrigo de Freitas, sudeste do Brasil

Six blooms of Heterosigma akashiwo (Raphidophyceae) were observed from March 2007 through March 2008 in the Rodrigo de Freitas Lagoon, a semi-confined eutrophic system located in Rio de Janeiro state, southeast Brazil. Vegetative cells of H. akashiwo analysed by optical and electron microscopy showed morphology as described in the literature. The blooms (2.8 × 104 to 4 × 108 cell.L–1) were restricted to the middle section of the Piraquê Channel, which is situated in the northeastern part of the lagoon and receives freshwater inflow. The salinity of subsurface water and the channel depth showed significant negative correlations with H. akashiwo abundances, and appeared to restrict the blooms to this compartment of the lagoon. No fish mortality was associated with the H. akashiwo blooms, nor were brevetoxins detected in a cell extract obtained from the bloom observed on 19 March 2007.

Seis florações de Heterosigma akashiwo (Raphidophyceae) foram observadas em março de 2007 a março de 2008 na Lagoa Rodrigo de Freitas, um sistema semi-confinado eutrófico localizado no Rio de Janeiro (Sudeste do Brasil). As células vegetativas de H. akashiwo analisadas por microscopia óptica e eletrônica mostraram morfologia como descrito em literatura. As florações (2.8 × 104 a 4 × 108 cel.L–1) foram restritas à zona intermédia do canal Piraquê, que se situa na parte nordeste da lagoa e recebe aporte de água doce. A salinidade da sub-superfície da água e a profundidade do canal apresentaram correlação negativa significativa com a abundância de H. akashiwo e parecem determinar a formação de florações restritas a este compartimento da lagoa. Não houve mortalidade de peixes durante as florações de H. akashiwo e não foi detectada a presença de brevetoxinas em um extrato celular obtido a partir da floração observada em 19 de março de 2007.

Cirurgia cardíaca videoassistida: 6 anos de experiência / Video-assisted cardiac surgery: 6 years of experience

INTRODUÇÃO: A cirurgia cardíaca minimamente invasiva e videoassistida (CCVA) tem aumentado em popularidade nos últimos 15 anos. As pequenas incisões têm sido associadas a um bom efeito estético e menor trauma cirúrgico, consequentemente, menor dor e rápida recuperação pós-operatória. OBJETIVOS: Apresentar nossa casuística com CCVA, após 6 anos de uso do método. MÉTODOS: Cento e trinta e seis pacientes foram submetidos à CCVA, após consentimento escrito, entre setembro de 2005 e outubro de 2011, sendo 50% do sexo masculino, com idade de 47,8 ± 15,4 anos, divididos em dois grupos: com circulação extracorpórea (CEC) (GcCEC=105 pacientes): valvopatia mitral (47/105), valvopatia aórtica (39/105) e cardiopatia congênita (19/105) e sem CEC (GsCEC=31 pacientes): ressincronização cardíaca (18/31), tumor cardíaco (4/31) e revascularização miocárdica minimamente invasiva (6/31). No GcCEC, foi realizada minitoracotomia direita (3 a 5 cm) e acesso femoral para canulação periférica. RESULTADOS: No GcCEC, a média de dias em UTI (DUTI) e de internação hospitalar (DH) foi, respectivamente, 2,4 ± 4,5 dias e 5,0 ± 6,8 dias. Doze pacientes apresentaram complicações no pós-operatório e cinco (4,8%) foram a óbito. Noventa e três (88,6%) pacientes evoluíram sem intercorrências, foram extubados no centro cirúrgico, permanecendo 1,8 ± 0,9 DUTI e 3,6 ± 1,3 DH. No GsCEC, foram 1,3 ± 0,7 DUTI e 2,9 ± 1,4 DH, sem intercorrências ou óbitos. CONCLUSÃO: Os resultados encontrados nesta casuística são comparáveis aos da literatura mundial e confirmam o método como opção à técnica convencional.

INTRODUCTION: Minimally invasive and video-assisted cardiac surgery (VACS) has increased in popularity over the past 15 years. The small incisions have been associated with a good aesthetic effect and less surgical trauma, therefore less postoperative pain and rapid recovery. OBJECTIVES: To present our series with VACS, after 6 years of use of the method. METHODS: 136 patients underwent VACS, after written consent, between September 2005 and October 2011, 50% for men and age of 47.8 ± 15, 4anos, divided into two groups: with cardiopulmonary (CEC) (GcCEC=105 patients): mitral valve disease (47/105), aortic disease (39/105), congenital heart disease (19/105) and without extracorporeal circulation (CEC) (GsCEC=31 patients): cardiac resynchronization (18/ 31), cardiac tumor (4/31) and minimally invasive coronary artery bypass grafting (6/31). GcCEC was held in right minithoracotomy (3 to 5 cm) and femoral access to perform cannulation. RESULTS: In GcCEC, mean length of ICU stay and hospital stay were respectively 2.4 ± 4.5 days and 5.0 ± 6.8 days. Twelve patients presented complications in post-operative and five (4.8%) death. Ninety-three (88.6%) patients evolved uneventful, were extubated in operating room, and remained a mean of 1.8 ± 0.9 days in ICU and 3.6±1.3 days in the hospital. In GsCEC, were mean 1.3 ± 0.7 days in ICU and 2.9 ± 1.4 days in hospital and without complications or deaths. CONCLUSION: The results found in this series are comparable to those of world literature and confirm the method as an option the conventional technique.

Low expression of APAF-1XL in acute myeloid leukemia may be associated with the failure of remission induction therapy

Apoptotic protease activating factor 1 (APAF-1) has a critical role in the regulation of apoptosis. In the present study, the mRNA expression analysis of different APAF-1 transcripts (APAF-1S, APAF-1LC, APAF-1LN, and APAF-1XL) was analyzed in bone marrow samples from 37 patients with acute myeloid leukemia (newly diagnosed, with no previous treatment). APAF-1XL and APAF-1LN transcripts (with and without an extra WD-40 repeat region, respectively) were detected in all samples, although the major form expressed was APAF-1XL in 65 percent of the samples (group 1), while 35 percent of the samples expressed primarily APAF-1LN (group 2). Only 46 percent of the patients presented complete remission in response to remission induction therapy (represented by less than 5 percent marrow blasts and hematological recovery), all but 2 cases being from group 1, 21.6 percent did not attain complete remission (only 1 case from group 1), and 32.4 percent of the patients died early. Lower expression of APAF-1XL (APAF-1XL/APAF-1LN ratio <1.2) was associated with a poor response to therapy (P = 0.0005, Fisher exact test). Both groups showed similar characteristics regarding white blood cell counts, cytogenetic data or presence of gene rearrangements associated with good prognosis as AML1-ETO, CBFB-MYH11 and PML/RARA. Since it has been shown that only the isoforms with the extra WD-40 repeat region activate procaspase-9, we suggest that low procaspase-9 activation may also be involved in the deregulation of apoptosis and chemotherapy resistance in acute myeloid leukemia.

A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group

The objective of this multicenter prospective study was to determine the clinical efficacy and toxicity of a polychemotherapeutic third generation regimen, VACOP-B, with or without radiotherapy as front-line therapy in aggressive localized non-Hodgkin's lymphoma. Ninety-three adult patients (47 males and 46 females, median age 45 years) with aggressive localized non-Hodgkin's lymphoma, 43 in stage I and 50 in stage II (non-bulky), were included in the study. Stage I patients received VACOP-B for 6 weeks plus involved field radiotherapy and stage II patients received 12 weeks VACOP-B plus involved field radiotherapy on residual masses. Eighty-six (92.5 percent) achieved complete remission and 4 (4.3 percent) partial remission. Three patients (3.2 percent) were primarily resistant. Ten-year probability of survival, progression-free survival and disease-free survival were 87.3, 79.9 and 83.9 percent, respectively. Eighty-four patients are surviving at a median observation time of 57 months (range: 6-126). Statistical analysis showed no difference between stages I and II in terms of response, ten-year probability of survival, progression-free survival or disease-free survival. Side effects and toxicity were negligible and were similar in the two patient groups. The results of this prospective study suggest that 6 weeks of VACOP-B treatment plus radiotherapy may be the therapy of choice in stage I aggressive non-Hodgkin's lymphoma. Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma.

The availability of full match sibling donors and feasibility of allogeneic bone marrow transplantation in Brazil

The feasibility of allogeneic bone marrow transplantation (alloBMT) in a developing country has not yet been demonstrated. Many adverse factors including social and economic limitations may reduce the overall results of this complex and expensive procedure. Our objective was to characterize the most important clinical, social and economic features of candidates for transplantation and their potential donors as well as the influence of these factors on overall survival in a retrospective and exploratory analysis at a university hospital. From July 1993 to July 2001, candidates for BMT were referred to the Bone Marrow Transplantation Unit by Hematology and Oncology Centers from several regions of Brazil. A total of 1138 patients were referred to us as candidates for alloBMT. Median age was 25 years (range: 2 months-60 years), 684 (60.1 percent) were males and 454 (39.9 percent) were females. The clinical indications were severe aplastic anemia and hematological malignancies. From the total of 1138 patients, 923 had HLA-typing; 497/923 (53.8 percent) candidates had full match donors; 352/1138 (30.8 percent) were eligible for alloBMT. Only 235 of 352 (66.7 percent) were transplanted. Schooling was 1st to 8th grade for 123/235 (52.3 percent); monthly family income ranged from US$60 (7 percent) to more than US$400 (36 percent). Overall survival for patients with chronic myeloid leukemia, severe aplastic anemia and acute myeloid leukemia was 58, 60 and 30 percent, respectively. Thus, overall survival rates for the most frequent hematological diseases were similar to those reported in the International Registry, except for acute myeloid leukemia. This descriptive and exploratory analysis suggests the feasibility of alloBMT in a developing country like Brazil

High-dose cyclophosphamide followed by autologous peripheral blood progenitor cell transplantation improves the salvage treatment for persistent or sensitive relapsed malignant lymphoma

Trials have demonstrated that high-dose escalation followed by autologous transplantation can promote better long-term survival as salvage treatment in malignant lymphomas. The aim of the present nonrandomized clinical trial was to demonstrate the role of high-dose cyclophosphamide (HDCY) in reducing tumor burden and also to determine the effectiveness of HDCY followed by etoposide (VP-16) and methotrexate (MTX) in Hodgkin's disease plus high-dose therapy with peripheral blood progenitor cell (PBPC) transplantation as salvage treatment. From 1998 to 2000, 33 patients with a median age of 33 years (13-65) affected by aggressive non-Hodgkin's lymphoma (NHL) (60.6 percent) or persistent or relapsed Hodgkin's disease (39.4 percent) were enrolled and treated using high dose escalation (HDCY + HDVP-16 plus HDMTX in Hodgkin's disease) followed by autologous PBPC transplantation. On an "intention to treat" basis, 33 patients with malignant lymphomas were evaluated. The overall median follow-up was 400 days (40-1233). Thirty-one patients underwent autografting and received a median of 6.19 x 10(6)/kg (1.07-29.3) CD34+ cells. Patients who were chemosensitive to HDCY (N = 22) and patients who were chemoresistant (N = 11) presented an overall survival of 96 and 15 percent, respectively (P<0.0001). Overall survival was 92 percent for chemosensitive patients and 0 percent for patients who were still chemoresistant before transplantation (P<0.0001). Toxicity-related mortality was 12 percent (four patients), related to HDCY in two cases and to transplant in the other two. HDCY + HDVP-16 plus HDMTX in only Hodgkin's disease followed by autologous PBPC proved to be effective and safe as salvage treatment for chemosensitive patients affected by aggressive NHL and Hodgkin's disease, with acceptable mortality rates related to sequential treatment

Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study

Clinical trials indicate that amifostine may confer protection on various normal tissues without attenuating anti-tumor response. When administered prior to chemotherapy or radiotherapy, it may provide a broad spectrum of cytoprotection including against alkylating drugs. The mechanism of protection resides in the metabolism at normal tissue site by membrane-bound alkaline phosphatase. Toxicity of this drug is moderate with hypotension, nausea and vomiting, and hypocalcemia being observed. We report a phase II study using amifostine as a protective drug against high-dose cyclophosphamide (HDCY) (7 g/m2), used to mobilize peripheral blood progenitor cells (PBPC) and to reduce tumor burden. We enrolled 29 patients, 22 (75.9 percent) affected by aggressive and 7 (24.1 percent) by indolent non-Hodgkin's lymphoma (NHL), who were submitted to 58 infusions of amifostine and compared them with a historical group (33 patients) affected by aggressive NHL and treated with VACOP-B followed by HDCY. The most important results in favor of amifostine were the reduction of intensity of cardiac, pulmonary and hepatic toxicity, and a significant reduction of frequency and severity of mucositis (P = 0.04). None of the 29 patients died in the protected group, while in the historical group 2/33 patients died because of cardiac or pulmonary toxicity and 2 patients stopped therapy due to toxicity. Amifostine did not prevent the aplastic phase following HDCY. PBPC collection and hematological recovery were adequate in both groups. The number of CFU-GM (colony-forming units-granulocyte/macrophage) colonies and mononuclear cells in the apheresis products was significantly higher in the amifostine group (P = 0.02 and 0.01, respectively). Side effects were mild and easily controlled. We conclude that amifostine protection should be useful in HDCY to protect normal tissues, with acceptable side effects.

Mise en evidence de phytosteroides antifongiques contre cryptococcus neoformans

Par des methodes simples d'extraction; de chromatographie sur colonne de SEPHADEX de filtration G50; et par des reactions colorees; les auteurs ont mis en evidence la presence unique de phytosterols dans la fraction ethanolique (F2) d'un extrait foliaire de mitracapus verticillatus; valke; (Rubiacee). L'activite antifongique de ces phytosterols a ete testee sur cryptococcus neoformans; un germe fongique implique dans la redoutable meningite a cryptocoque. La culture du cryptocoque sur agar Sabouraud/chloramphenicol incorpore a F2 en double dilution a donne une concentration minimale fongique (CMF) egale a 12 gammas (12 ug/ml) quand l'extrait total (Et) donne 768 ug/ml et sa fraction 80acqueuse (F1) 2500 ug/ml. Un dosage chimique des ions a revele egalement la presence d'iode (I-) et de baryum (Ba++)qui confirme le pouvoir antiseptique et medical de la fraction (F2)

A psychiatric evaluation of referred cancer and medical patients: a comparative study.

We evaluated the psychiatric status of referred cancer patients (N = 39) and referred medical patients at two other institutions (N = 64, N = 62). Depression, anxiety, psychosis, delirium occurred with comparable frequency in both groups. Cancer patients presented with somatic complaints more frequently. However the average number of referrals of cancer patients to the psychiatric service was very low (3/months) compared to referral of medically ill patients (32/month, 10/month). The data suggests that a comparable level of psychological distress exists in cancer patients, and psychiatric referral may help in its early recognition and alleviation.

Etude de l'activite antimicrobienne des extraits aqueux totaux de dix plantes medicinales

Les effets antimicrobiens de dix plantes couramment utilisees dans le traitement traditionnel de certaines maladies infectieuses ont ete etudies. Nos resultats indiquent que les extraits aqueux totaux de ces plantes inhibent a des degres divers la croissance in vitro de plusieurs bacteries. Ces resultats peuvent expliquer; dans le cas de certaines plantes; leur indication therapeutique traditionnelle